Allergan acquires Chase for a possible $1bn
Allergan PLC acquired private neurodegenerative therapeutics biotech Chase Pharmaceuticals Corp. (focused improving the symptomatic treatment of Alzheimer’s disease) for up to $1bn.
- Drug Delivery
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.